section name header

Pronunciation

my-ka-FUN-gin

Classifications

Therapeutic Classification: antifungals

Pharmacologic Classification: echinocandins

Indications

REMS


Action

  • Inhibits synthesis of glucan required for the formation of fungal cell wall.
Therapeutic effects:
  • Death of susceptible fungi.

Spectrum:

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Primarily distributed into lung, liver, and spleen; minimal distribution to CNS and eyes.

Protein Binding: >99%.

Metabolism/Excretion: Mostly metabolized in the liver; 71% fecal elimination.

Half-Life: 15 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
IVrapidend of infusion24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: worsening hepatic function/hepatitis

GU: renal impairment

Hemat: hemolysis/hemolytic anemia

Local: injection site reactions

Misc: infusion reactions, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Route/Dosage

Treatment of Esophageal Candidiasis

Treatment of Candidemia/Acute Disseminated Candidiasis/Candida Peritonitis and Abscesses

Treatment of Candidemia/Acute Disseminated Candidiasis/Candida Peritonitis and Abscesses Without Meningoencephalitis and/or Ocular Dissemination

Prophylaxis of Candida Infections During Hematopoetic Stem Cell Transplantation

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Mycamine